# Extension Study for the Port Delivery System With Ranibizumab (Portal)

> **NCT03683251** · PHASE3 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 1000 (estimated)

## Conditions studied

- Neovascular Age-Related Macular Degeneration

## Interventions

- **DRUG:** PDS Implant with Ranibizumab 100 mg/mL

## Key facts

- **NCT ID:** NCT03683251
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-09-20
- **Primary completion:** 2029-10-31
- **Final completion:** 2029-10-31
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03683251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03683251, "Extension Study for the Port Delivery System With Ranibizumab (Portal)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03683251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*